SGEN Seattle Genetics, Inc.

65.57
-0.45  -1%
Previous Close 66.02
Open 66.07
Price To book 15.61
Market Cap 9.36B
Shares 142,716,000
Volume 421,987
Short Ratio 11.71
Av. Daily Volume 685,333

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced August 19, 2011.
ADCETRIS
Hodgkin lymphoma and Anaplastic large cell lymphoma
Phase 1/2 clinical hold placed on December 27, 2016 was lifted March 6, 2017.
Vadastuximab Talirine (SGN-CD33A)
Myelodysplastic syndrome (MDS)
Phase 3 initiated May 2016. Enrollment ongoing as of April 2017.
Vadastuximab Talirine (CASCADE)
Acute myeloid leukemia (AML) - cancer
Phase 3 data due in 2017.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
SGN-CD19A
Frontline DLBCL cancer
Phase 3 enrollment completed November 2016. Data are due in 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Approved August 17, 2015 under priority review.
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
Phase 3 data released August 2016. sNDA to be filed mid 2017.
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma

Latest News

  1. Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : May 19, 2017
  2. Seattle Genetics to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
  3. The Head-Scratching Reason Immunomedics Rose by as Much as 12%
  4. Immunomedics Breaks Out, But Will It Last?
  5. Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated?
  6. Immunomedics, Seattle Genetics Scrap License Deal
  7. Why Immunomedics, Inc. Rocketed Today
  8. Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated
  9. Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132)
  10. ETFs with exposure to Seattle Genetics, Inc. : May 4, 2017
  11. Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017
  12. Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : May 3, 2017
  13. Seattle Genetics, Inc. Earnings: Solid Quarter, but Investors Wait
  14. Edited Transcript of SGEN earnings conference call or presentation 27-Apr-17 8:30pm GMT
  15. Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates
  16. Seattle Genetics reports 1Q loss
  17. Seattle Genetics Reports First Quarter 2017 Financial Results
  18. Investor Network: Seattle Genetics, Inc. to Host Earnings Call
  19. Why Immunomedics, Inc. Got Hammered Today
  20. Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : April 14, 2017